Amneal Pharmaceuticals (AMRX) announced the U.S. launch of albuterol sulfate inhalation aerosol and beclomethasone dipropionate HFA inhalation aerosol.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals Earnings Call: Growth Amid Transition
- Amneal Pharmaceuticals price target raised to $17 from $15 at Goldman Sachs
- Amneal Pharmaceuticals price target raised to $17 from $15 at Truist
- Truist ups Amneal Pharmaceuticals price target, says pullback great entry point
- Amneal Pharmaceuticals: Portfolio Shift to High-Margin Brands and Biosimilars Supports Buy Rating and Upside to $17 Target